Detalles de la búsqueda
1.
Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.
Dermatol Ther
; 33(4): e13487, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32362053
2.
Malassezia-derived aryl hydrocarbon receptor ligands enhance the CCL20/Th17/soluble CD163 pathogenic axis in extra-mammary Paget's disease.
Exp Dermatol
; 28(8): 933-939, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31001887
3.
A novel technique to diagnose non-melanoma skin cancer by thermal conductivity measurements: Correlations with cancer stromal factors.
Exp Dermatol
; 28(9): 1029-1035, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31264287
4.
Minocycline decreases Th2 chemokines from M2 macrophages: Possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs.
Exp Dermatol
; 27(11): 1268-1272, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30192415
5.
Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages.
Exp Dermatol
; 27(1): 64-70, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28833504
6.
Acquired Idiopathic Generalized Anhidrosis: An Immunohistopathological Investigation of Peri-glands Infiltrated with Immunoreactive Cells.
Acta Derm Venereol
; 95(6): 743-4, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25519938
7.
Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.
Melanoma Res
; 30(6): 613-618, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32658051
8.
Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma.
Front Immunol
; 11: 534323, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33178182
9.
Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
J Dermatol
; 47(6): 654-657, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32293049
10.
Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy.
Case Rep Oncol
; 13(1): 271-275, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32308589
11.
Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.
J Dermatol
; 47(6): 636-640, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32207181
12.
Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy.
J Dermatol
; 46(5): 449-452, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30908705
13.
Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection.
Front Med (Lausanne)
; 6: 140, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31297373
14.
Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma.
Front Oncol
; 9: 907, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31616630
15.
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma.
Front Med (Lausanne)
; 6: 86, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31080803
16.
Widely Spread Unilateral Inflammatory Linear Verrucous Epidermal Nevus (ILVEN).
Case Rep Dermatol
; 10(2): 170-175, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30022937
17.
Keratoacanthoma Centrifugum Marginatum with Spontaneous Regression and Its Possible Differential Diagnosis.
Case Rep Oncol
; 11(3): 671-675, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30483096
18.
Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod.
Case Rep Oncol
; 11(1): 1-5, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29515401
19.
Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy.
Case Rep Oncol
; 11(1): 29-32, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29515406
20.
The Expression of Matrix Metalloproteinases in Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-expressing Cancer of Apocrine Origin.
Anticancer Res
; 38(1): 113-120, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29277763